Limits...
The effects of bromocriptine on preventing postpartum flare in systemic lupus erythematosus patients from South China.

Qian Q, Liuqin L, Hao L, Shiwen Y, Zhongping Z, Dongying C, Fan L, Hanshi X, Xiuyan Y, Yujin Y - J Immunol Res (2015)

Bottom Line: All the patients were followed up for 12 months.Clinical features were recorded every 4 weeks.Two weeks of oral bromocriptine treatment in postpartum SLE patients may relieve the disease from hyperprolactinemia and hyperestrogenemia and may be beneficial in preventing the patients from disease relapse.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.

ABSTRACT

Objective: Prolactin plays an important role on the disease flare of postpartum SLE patients. 76 pregnant SLE patients were enrolled in this study to evaluate the efficacy of bromocriptine (an inhibitor of prolactin secretion) on preventing the postpartum disease relapse.

Methods: Patients were randomly divided into the treatment group (bromocriptine, 2.5 mg oral, twice a day for 14 days after delivery) and the control group. All the patients were followed up for 12 months. Clinical features were recorded every 4 weeks. Serum prolactin and estradiol levels were measured at the second week and the second month after delivery. The endpoint of the study was disease relapse and defined when SLEDAI score increased by ≥3 points from the antenatal baseline.

Results: (1) Serum levels of prolactin and estradiol decreased significantly in bromocriptine treatment group at the second week (P < 0.001) and second month (P < 0.05) after delivery compared to control group. (2) The relapse rate of the treatment group was lower than the control group (χ (2) = 4.68, P = 0.0305).

Conclusions: Two weeks of oral bromocriptine treatment in postpartum SLE patients may relieve the disease from hyperprolactinemia and hyperestrogenemia and may be beneficial in preventing the patients from disease relapse.

No MeSH data available.


Related in: MedlinePlus

Study design. SLEDAI: systemic lupus erythematosus disease activity index.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4418009&req=5

fig1: Study design. SLEDAI: systemic lupus erythematosus disease activity index.

Mentions: 95 pregnant SLE patients hospitalized in our hospital between July 2003 and October 2013 were recruited. The study design is presented in Figure 1. Local Ethics Committee approved the protocol and written informed consents were obtained. All patients fulfilled at least 4 of the American College of Rheumatology criteria for SLE [13]. Pregnant lupus patients with inactive or mild-active SLE receiving no more than 10 mg of prednisone (or equivalent) per day were eligible for this study. Disease activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [14]. Patients were defined as inactive SLE when the SLEDAI scores ≤4 and mild-active with the scores between 5 to 9. Patients were excluded if they (1) had a SLEDAI score ≥10; (2) had proteinuria >500 mg/24 hours or other major organ system involvements; (3) were receiving >10 mg/day of prednisone (or equivalent) during pregnancy; or (4) had a serum level of complement 3 < 0.5 g/L.


The effects of bromocriptine on preventing postpartum flare in systemic lupus erythematosus patients from South China.

Qian Q, Liuqin L, Hao L, Shiwen Y, Zhongping Z, Dongying C, Fan L, Hanshi X, Xiuyan Y, Yujin Y - J Immunol Res (2015)

Study design. SLEDAI: systemic lupus erythematosus disease activity index.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4418009&req=5

fig1: Study design. SLEDAI: systemic lupus erythematosus disease activity index.
Mentions: 95 pregnant SLE patients hospitalized in our hospital between July 2003 and October 2013 were recruited. The study design is presented in Figure 1. Local Ethics Committee approved the protocol and written informed consents were obtained. All patients fulfilled at least 4 of the American College of Rheumatology criteria for SLE [13]. Pregnant lupus patients with inactive or mild-active SLE receiving no more than 10 mg of prednisone (or equivalent) per day were eligible for this study. Disease activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [14]. Patients were defined as inactive SLE when the SLEDAI scores ≤4 and mild-active with the scores between 5 to 9. Patients were excluded if they (1) had a SLEDAI score ≥10; (2) had proteinuria >500 mg/24 hours or other major organ system involvements; (3) were receiving >10 mg/day of prednisone (or equivalent) during pregnancy; or (4) had a serum level of complement 3 < 0.5 g/L.

Bottom Line: All the patients were followed up for 12 months.Clinical features were recorded every 4 weeks.Two weeks of oral bromocriptine treatment in postpartum SLE patients may relieve the disease from hyperprolactinemia and hyperestrogenemia and may be beneficial in preventing the patients from disease relapse.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.

ABSTRACT

Objective: Prolactin plays an important role on the disease flare of postpartum SLE patients. 76 pregnant SLE patients were enrolled in this study to evaluate the efficacy of bromocriptine (an inhibitor of prolactin secretion) on preventing the postpartum disease relapse.

Methods: Patients were randomly divided into the treatment group (bromocriptine, 2.5 mg oral, twice a day for 14 days after delivery) and the control group. All the patients were followed up for 12 months. Clinical features were recorded every 4 weeks. Serum prolactin and estradiol levels were measured at the second week and the second month after delivery. The endpoint of the study was disease relapse and defined when SLEDAI score increased by ≥3 points from the antenatal baseline.

Results: (1) Serum levels of prolactin and estradiol decreased significantly in bromocriptine treatment group at the second week (P < 0.001) and second month (P < 0.05) after delivery compared to control group. (2) The relapse rate of the treatment group was lower than the control group (χ (2) = 4.68, P = 0.0305).

Conclusions: Two weeks of oral bromocriptine treatment in postpartum SLE patients may relieve the disease from hyperprolactinemia and hyperestrogenemia and may be beneficial in preventing the patients from disease relapse.

No MeSH data available.


Related in: MedlinePlus